Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 50 of 5804
-
New cocktail approach aims to wipe out High-Risk rectal cancer without surgery
Disease control Recruiting nowTo explore the efficacy and safety of short-course radiotherapy combined with mFOLFOX6, PD-1 monoclonal antibody and cetuximab (for RAS/BRAF Wild-Type)/bevacizumab (for RAS/BRAF Mutant) in High-Risk pMMR/MSS Rectal Adenocarcinoma through a prospective study, providing high-level …
Phase: PHASE2 • Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
AI predicts deadly gut infection in preemies days before it strikes
Diagnosis Recruiting nowPrematurity affects around 7% of births in France. Necrotizing enterocolitis (NEC) is a dreaded digestive complication. It is responsible for a mortality rate ranging from 15 to 40%, a rate that has remained stable in recent years, and for medium- and long-term digestive and neur…
Phase: NA • Sponsor: University Hospital, Clermont-Ferrand • Aim: Diagnosis
Last updated Jun 27, 2026 12:04 UTC
-
New combo therapy aims to beat leukemia without harsh chemo
Disease control Recruiting nowThis is a single-arm, prospective, phase 2 clinical trial evaluating the improvement of survival outcomes of blinatumomab combined with chemotherapy as a full-course treatment regimen in patients with newly diagnosed Philadelphia chromosome-negative (Ph-negative) B-cell precursor…
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug cocktail aims to outsmart childhood brain tumors
Disease control Recruiting nowPediatric gliomas harboring BRAF-alterations, commonly BRAFV600 mutation or KIAA1549-BRAF fusion, are currently treated with either chemotherapy or mitogen activated protein kinase (MAPK) inhibitors, such as, dabrafenib and/or trametinib. Unfortunately, some BRAF-altered gliomas …
Phase: PHASE1, PHASE2 • Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Could this Stem-Cell infusion end insulin shots for diabetics with kidney transplants?
Disease control Recruiting nowThis study will evaluate the efficacy, safety, and tolerability of VX-880 in participants with Type 1 Diabetes (TID) with a kidney transplant.
Phase: PHASE3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New hope for lung cancer patients when targeted drugs stop working
Disease control Recruiting nowTo evaluate the efficacy and safety of SYS6010 versus platinum-based chemotherapy in participants with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC)
Phase: PHASE3 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Promising new combo aims to tame childhood leukemia with less chemo
Disease control Recruiting nowThis prospective clinical trial evaluates the effectiveness and safety of "chemotherapy-light" regimen incorporating the third-generation TKI olverembatinib, the bi-specific CD3/CD19 T cell engager blinatumomab, and the BCL-2 selective inhibitor venetoclax for newly diagnosed ped…
Phase: PHASE3 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 26, 2026 13:22 UTC
-
Gene therapy gel aims to stop skin cancer from coming back in RDEB patients
Disease control Recruiting nowThe study objective is to see if BVEC induced C7 expression in Recessive Dystrophic Epidermolysis Bullosa (RDEB) skin following Squamous cell carcinoma (SCC) excision will normalize the invasive tumor microenvironment and reduce tumor recurrence. Prevention of SCC's in the RDEB …
Phase: PHASE2 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New pulsed suction device aims to clear stroke clots faster
Disease control Recruiting nowThe goal of this clinical trials is to demonstrate the safety and effectiveness for the RapidPulseTM Aspiration System in patients experiencing acute ischemic stroke within 8 hours of symptom onset or last seen normal. Subjects will undergo mechanical thrombectomy (a procedure to…
Phase: NA • Sponsor: RapidPulse, Inc • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Gene therapy mends wounds in rare 'butterfly skin' disease
Disease control OngoingThe purpose of this study is to determine whether administration of D-Fi in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Dystrophic Epidermolysis Bullosa.
Phase: PHASE3 • Sponsor: Castle Creek Biosciences, LLC. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Could an mRNA vaccine stop chlamydia? new trial begins
⭐️ VACCINE ⭐️ Recruiting nowThe purpose of this study is to evaluate the safety, efficacy, and immunogenicity of different dose levels (low, medium, and high) of Chlamydia messenger ribonucleic acid (mRNA) Vaccine candidate in adult participants aged 18 to 29 years. This study will consist of 3 Sentinel Co…
Phase: PHASE1, PHASE2 • Sponsor: Sanofi • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:05 UTC
-
New drug cocktail aims to outsmart aggressive uterine cancer
Disease control Recruiting nowDESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by B…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug combo aims to tackle tough lung cancer mutation
Disease control Recruiting nowThe main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab i…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New hope for babies: drug targets rare genetic disorder that hardens arteries
Disease control Recruiting nowThe primary purpose of ENERGY 2 (Study INZ701-105) is to assess the efficacy and safety of INZ-701 in infants with ENPP1 Deficiency.
Phase: PHASE3 • Sponsor: Inozyme Pharma • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Could your own lung cells heal COPD? a new stem cell trial aims to find out
Disease control Recruiting nowThis clinical trial aims to evaluate the safety and efficacy of REGEND001, an autologous bronchial basal cell therapy, for the treatment of Chronic Obstructive Pulmonary Disease (COPD). COPD is a chronic respiratory condition characterized by persistent airflow limitation and imp…
Phase: PHASE1, PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
CRISPR gene editing offers hope for sickle cell patients
Disease control Recruiting nowThis study is being done to test the safety of a new treatment called gene editing in Sickle Cell Disease (SCD) patients and to see if a single dose of this genetically modified cellular product will increase the amount of a certain hemoglobin called fetal hemoglobin (HbF) and he…
Phase: PHASE1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for aggressive breast cancer: targeted drug combo shows promise in early trial
Disease control Recruiting nowResearchers are looking for new ways to treat triple-negative breast cancer (TNBC) and hormone receptor (HR) low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. The main goals of this study are to learn: * About the safety of the study treatments…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New malaria vaccine trial aims to protect women and their future babies
⭐️ VACCINE ⭐️ OngoingThis will be a double-blind, individually randomised trial, to assess the safety, tolerability, immunogenicity, and protective efficacy of two and three doses of the R21/Matrix-M1 malaria vaccine or placebo given at 4 week intervals in healthy women of childbearing potential (WOC…
Phase: PHASE2 • Sponsor: University of Oxford • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:08 UTC
-
New hope for Crohn's: phase 3 trial of afimkibart launches
Disease control Recruiting nowThis Phase III, multicenter, double-blind, placebo-controlled treat-through study will evaluate the efficacy and safety of induction and maintenance therapy with Afimkibart (also known as RO7790121) in participants with moderately to severely active Crohn's disease (CD).
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Brain cancer vaccine shows promise in new trial
Disease control Recruiting nowThe goal of this clinical trial is to learn if DOC1021 + pIFN alongside standard of care (SOC) will improve survival in adult patients newly diagnosed with glioblastoma (IDH-wt). It will also evaluate the safety of DOC1021 + pIFN. Researchers will compare DOC1021 dendritic cell i…
Phase: PHASE2 • Sponsor: Diakonos Oncology Corporation • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC